BACKGROUND INFORMATION ON THE PROCEDURE 
1.  Submission of the dossier 
The  applicant  Bristol-Myers  Squibb  Pharma  EEIG  submitted  on  12  January 2006  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Sprycel,  which  was 
designated  as  an  orphan  medicinal  product  EU/3/05/338  (ALL)  and  EU/3/05/339  (CML)  on  
23 December 2005. Sprycel was designated as an orphan medicinal product for the tretment of chronic 
myeloid  leukemia  (CML)  and  for  the  treatment  of  acute  lymphoblastic  leukemia  (ALL):.  The 
calculated prevalence of this condition was 0.71 per 10,000 EU population (ALL) and 0.9 per 10,000 
EU population (CML). 
The  applicant  applied  for  the  following  therapeutic  indication:  Treatment  of  adult  patients  with 
chronic myeloid leukaemia (CML) with resistance  or  intolerance to prior therapy including imatinib 
mesylate, or with Philadelphia chromosome positive (Ph+) ALL with resistance or intolerance to prior 
therapy. 
The legal basis for this application refers to: 
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
Similarity: 
Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) 
No  847/2000,  the  application  contained  a  critical  report  addressing  the  possible  similarity  with 
authorised orphan medicinal products Glivec and Evoltra. 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 21 October 2004. The Scientific Advice 
pertained to clinical development aspects of the dossier. 
Licensing status: 
A new application was filed in the following countries: U.S.A 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Jens Ersbøll 
Co-Rapporteur:  Beatriz Silva Lima 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 12 January 2006. 
The procedure started on 1 February 2006. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  24  April 
2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
26. April 2006.  
The CHMP adopted a report on similarity of Sprycel with Glivec on 27 April 2006. 
During the meeting on 29 May to 1 June 2006, the CHMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 1 June 2006. 
During the meeting on 26-29 June 2006, the CHMP agreed on an addendum to the consolidated 
List  of  Questions  to  be  sent  to  the  applicant.  The  addendum  to  the  consolidated  List  of 
Questions was sent to the applicant on 4 July 2006. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 13 July 
2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 30 August 2006. 
©EMEA 2006 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
The CHMP adopted a report on similarity of Sprycel with Evoltra on 21 September 2006. 
During  the  meeting  on  18-21  September  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Sprycel on 21 September 2006. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  21 
September 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 20 November 2006. 
©EMEA 2006 
2/2 
 
